论文部分内容阅读
目的探讨核苷酸切除修复交叉互补基因1(ERCC1)蛋白表达及其基因多态性与食管鳞状上皮细胞癌患者生存期的关系,为食管鳞状上皮细胞癌防治提供参考依据。方法于2011年1月—2012年10月在浙江省台州市立医院肿瘤外科随机抽取108例食管鳞状上皮细胞癌术后行辅助化疗患者,采用免疫组化法检测ERCC1蛋白表达水平,并采用聚合酶链反应测定ERCC1基因C8092A、C118T 2个位点的等位基因表达频率,分析ERCC1表达及其基因多态性与食管鳞状上皮细胞癌患者生存期的关系。结果 108例食管鳞状上皮细胞癌术后行辅助化疗患者中,ERCC1蛋白表达阳性者56例(51.9%),ERCC1蛋白表达阴性者52例(48.1%),ERCC1蛋白表达阳性者和阴性者的生存期中位数分别为29.7和31.4个月,差异无统计学意义(P>0.05);ERCC1基因C8092A位点上,等位基因CC患者19例(17.6%),CA患者44例(41.7%),AA患者45例(40.7%);ERCC1基因C118T位点上,等位基因CC患者65例(60.2%),CT患者30例(27.8%),TT患者13例(12.1%);C8092A位点等位基因CC和CA患者的生存时间中位数分别为31.5和32.0个月,均长于AA患者的24.5个月,差异均有统计学意义(均P<0.05);C118T位点等位基因CC、CT和TT患者的生存时间中位数分别为30.5、30.0和29.0个月,差异无统计学意义(P>0.05)。结论 ERCC1蛋白表达与鳞状上皮食管癌患者的生存期无明显关联,而ERCC1基因C8092A位点基因多态性与患者的生存期有一定关系。
Objective To investigate the relationship between the nucleotide excision repair cross-complementary gene 1 (ERCC1) gene expression and its gene polymorphism and the survival of patients with esophageal squamous cell carcinoma (ESCC), and to provide a reference for the prevention and treatment of esophageal squamous cell carcinoma. Methods From January 2011 to October 2012, 108 patients with esophageal squamous cell carcinoma (ESCC) undergoing adjuvant chemotherapy were randomly selected from the Department of Oncology, Taizhou Municipal Hospital of Zhejiang Province, and the expression of ERCC1 protein was detected by immunohistochemistry. The frequency of allele expression in ERCC1 gene C8092A and C118T was determined by enzyme linked immunosorbent assay. The relationship between the expression of ERCC1 and the gene polymorphism and the survival of patients with esophageal squamous cell carcinoma was analyzed. Results Among the 108 patients with esophageal squamous cell carcinoma who underwent adjuvant chemotherapy, 56 (51.9%) had ERCC1 protein positive, 52 (48.1%) had ERCC1 negative, ERCC1 positive and negative The median survival time was 29.7 and 31.4 months, respectively, with no significant difference (P> 0.05). In C8092A locus, 19 (17.6%) alleles and 44 (41.7%) patients had CA, , 45 patients (40.7%) with AA, 65 patients (60.2%) with allele CC, 30 patients (27.8%) with CT, and 13 patients (12.1%) with TT in C118T locus of ERCC1 gene. The median survival time of patients with allele CC and CA was 31.5 and 32.0 months, respectively, both longer than that of AA patients (P <0.05). The C118T allele CC The median survival time of patients with CT and TT were 30.5, 30.0 and 29.0 months, respectively, with no significant difference (P> 0.05). Conclusion There is no significant correlation between the expression of ERCC1 protein and the survival of patients with squamous epithelial esophageal cancer. However, the gene polymorphism of ERCC1 gene C8092A is associated with the survival of patients with esophageal squamous cell carcinoma.